BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Bio Reports

8 APAC Assets That Went Global The Out-Licensing Class of 2025 to 2026

Business development teams across the region keep arriving at the same question, phrased slightly differently each time. What did a comparable asset, at a ...

July 29, 2026 | Analysis

APAC Physicians Back Pulsed Field Ablation, But Referral Gaps Delay AFib Treatment

Growing physician confidence in pulsed field ablation highlights the need to strengthen referral pathways, education and healthcare system readiness - Bos...

July 29, 2026 | News

Stopped: The Six-Year Cost of Trials That Never Reached the Finish Line

One infusion, no programme A gene therapy is a one-way door. The vector goes in once, it cannot be taken out, and with current adeno-associated virus tech...

July 28, 2026 | Analysis

Laminar Pharma Completes Pivotal Phase 2b/3 Trial of LAM561 in Newly Diagnosed Glioblastoma

Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid therapy approach, announced that the last patient has c...

July 27, 2026 | News

Ribo’s Vortosiran Achieves 92% FXI Activity Reduction in Phase 2a Coronary Artery Disease Study

Suzhou Ribo Life Science Co., Ltd. (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") today announce at C...

July 24, 2026 | News

Discount or Validation? Western Pharma’s Appetite for Chinese Assets

There is a number that has stopped being a niche statistic for Asia-watchers and started reshaping where the global drug industry shops. The average upfron...

July 24, 2026 | Analysis

Top 26 Companies Leading Sustainable Biopharma Practices in 2026

Sustainability has stopped being a side conversation in the pharmaceutical industry. In 2026 it sits at the centre of how the sector defines leadership. Th...

July 23, 2026 | Analysis

The Bioreactors Are Ours. The Consumables Are Not.

A new biologics plant is one of the easier things in medicine to photograph. The bioreactors are large and gleaming, the capacity figures are big and round...

July 22, 2026 | Analysis

Rege Nephro Raises $10.6M to Advance iPS Cell-Based Kidney Disease Pipeline

inancing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline Rege Nephro Co., Ltd. ("Rege Nephr...

July 22, 2026 | News

Dimerix Acquires Phase II-Ready DMX-652 to Expand Kidney Disease Pipeline

Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New D...

July 20, 2026 | News

Neurizon Completes Rapid Phase II/III NUZ-001 Enrolment for ALS with Results Expected in Q2 2027

250 participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY AL...

July 20, 2026 | News

Two Chairs, 11,000 Kilometres Apart: The Human Cost of Asia’s Plasma Dependence

REPORTAGE / PLASMA SUPPLY THE CHAIR The chair reclines. That is the first thing you notice, walking into a plasma centre in a strip mall on...

July 17, 2026 | Analysis

China Plus One: Slogan, Strategy, or Capacity APAC Does Not Have?

THE RESHUFFLE · ANALYSIS On a Monday in June 2026, one line in the United States Federal Register did what two year...

July 16, 2026 | Analysis

Lynk Pharmaceuticals Completes Phase III Enrolment for Zemprocitinib in Ankylosing Spondylitis

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...

July 16, 2026 | News

Stay Connected